1 / 22

Immune Cell Therapy | Edward Cohen, M.D., Founder

Immune Cell Therapy | Edward Cohen, M.D., Founder. Cautionary Statement on Forward-Looking Information.

virgo
Download Presentation

Immune Cell Therapy | Edward Cohen, M.D., Founder

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Immune Cell Therapy| Edward Cohen, M.D., Founder

  2. Cautionary Statement on Forward-Looking Information Certain information contained in this presentation, including any information as to our strategy, projects, plans or future financial or operating performance and other statements that express management's expectations or estimates of future performance, constitute "forward-looking statements”. All statements, other than statements of historical fact, are forward-looking statements. The words “believe”, "expect", "will", “anticipate”, “contemplate”, “target”, “plan”, “continue”, “budget”, “may”, “intend”, “estimate” and similar expressions identify forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Immune Cell Therapy, Inc. cautions the reader that such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual financial results, performance or achievements of the company to be materially different from the company's estimated future results, performance or achievements expressed or implied by those forward-looking statements and the forward-looking statements are not guarantees of future performance. Such risks include but are not limited to: the ability to obtain financing immediately in current markets, the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceuticals industry, changes in the regulatory environment in the jurisdictions in which the Immune Cell Therapy, Inc. does business, fluctuations in costs, and changes to the competitive environment due to consolidation, achievement of forecasted burn rate, and that actual results may vary once the final and quality-controlled verification of data and analyses has been completed. Immune Cell Therapy, Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

  3. About Immune Cell Therapy, Inc. (ICT) ICT possesses the exclusive Intellectual Patent Property for the utilization of Allogeneic Cell Lines (ACL) in the modification and method of use in the treatment of human cancers. • Pre-clinical data provides strong evidence that the relative effects of ACL processes are highly immunogenic and efficacious • Personalized Cellular Vaccines for Lung Cancer • Vaccines for Breast Cancer

  4. Our Objective Adjuvant to current treatment methods with proprietary DNA-based vaccine methods developed by ICT that have shown evidence to be more effective at eliminating residual cancer cells in patients who have completed conventional treatment. NDA Clinical Studies Review Pre-Clinical Research Synthesis & Purification Animal Testing Institutional Review Boards Phase 1 First Patient Cancer FREE IND Submitted Phase 2 NDA Submitted Review Decision Review Decision Phase 3 Breast Cancer Vaccine IND Ready to be Filed Lung Cancer Vaccine Currently in Phase I Trial ICT Plans to Complete Phase I/II Clinical Trial of immunotherapy for 37 eligible patients with pathologically documented Non-Small Cell Lung Cancer (NSCLC)

  5. Our Team Edward Cohen, M.D Founder & Interim CEO Mary L. (Nora) Disis, M.D. Scientific Advisor Alice Lin-Tsing Yu, M.D., Ph.D. Scientific Advisor Sandra Gendler, Ph.D. Scientific Advisor Thomas Gajewski, M.D., Ph.D. Scientific Advisor

  6. How It Works DNA from the patient’s Cancer Cells is Transferred into Normal Cells from Unrelated Healthy Individual. • Normal cells from an unrelated healthy individual that take up DNA express cancer antigens. Normal Cells Normal Cells from Unrelated Healthy Individual Cancer Cells

  7. How It Works • Foreign cells expressing cancer antigens are taken up by patient’s dendritic cells. • Dendritic cells incorporate DNA from the foreign cells expressing cancer antigens. They activate killer T cells in the patient.

  8. How It Works • Activated T cells seek out cancer cells in the patient and destroy them. • Leaving normal patient cells intact

  9. Pre-Clinical Results Mice vaccinated had fully regressed tumor 35 days post-immunization with ICT Vaccine (LM-IL-2Kb/SB5b). SB5b + LM-IL-2Kb/SB5b SB5b + LM-IL-2Kb Increased Immune Response Increased Efficacy Target Stem Cell Markers SB5b + Media SB5b + LM-IL-2Kb/SB5b + CD8+ antibodies EP Cohen, Immunology Letters, Volume 74, Issue 1; September 15, 2000; pp. 59-65

  10. Pre-Clinical Results Extended survival seen with ICT Vaccine compared to Dendritic Cell Vaccine (DC/SCC) in mice with aggressive Squamous Cell Carcinoma (SCC). DC/SCC ICT Vaccine Anticancer Research 26; 2006; pp. 837-884

  11. Pre-Clinical Results Mice with melanoma treated solely by immunization with the ICT Vaccine developed strong, long-term resistance to the growth of the tumor. In some instances, the mice survived indefinitely. ICT Vaccine The Journal of Immunology, Vol. 160, No. 6; March 15, 1998; pp. 2915-2922

  12. Pre-Clinical Results Mice with breast cancer treated by immunization with ICT Vaccine survived more than 55 days without evident disease. They rejected the breast cancer cells. ICT Vaccine

  13. Early Phase 1 Progress First lung cancer patient who received conventional therapy* followed by immunization with ICT’s DNA-based vaccine has remained disease free with no toxicity for more than two years. Pathology Stage IIB Poorly diff. 6.5 cm adenocarcinoma with metastases ICT Vaccine *Taxotere/Cisplatin; **Case report in preparation.

  14. Why Immune Cell Therapy? ICT addresses key issues in Cancer Immunotherapy

  15. Benefits • Only small quantity of tumor tissue required • Vaccine specifies a broad array of tumor antigens and is personalized to patients tumor • Recipient cell line can be modified in advance to augment its inherent immunogenic properties (e.g., cytokine-secretion) • Number of vaccine cells can be expanded as required for multiple immunizations • Vaccine is conveniently and readily prepared at relatively low cost. Leukapheresis is not required • Non-Toxic • More Efficacious and Immunogenic than other Vaccine Approaches (Preclinical Head to Head Models)

  16. Milestones • Company-sponsored phase 1 clinical trial is ongoing. • Collaboration established with University of Pittsburgh Cancer Institute to conduct the trial. • Extensive patent portfolio protects technology (4 issued patents (US/Europe Coverage) and 2 Pending • In Excess of $2 Million in Grant and Venture Funding to date • IRB (Institutional Review Board) approval obtained for phase I Lung Cancer Study • FDA-approved human cells/facilities to prepare vaccine are on-hand • IND (Investigational New Drug) issued for Lung Cancer Vaccine • Phase I/II toxicity/efficacy study. • Permission granted to treat up to 37 lung cancer patients. • Only Lung Cancer Vaccine in clinical trials that targets multiple epitopes unique to the patient’s tumor (Lucanix in Phase 3 development in lung cancer targets only TGF-Beta. • Extensive Preclinical In Vitro and In Vivo research validates technology and efficacy 2006 to Present

  17. Patents

  18. Competition ImmunoCellular Therapeutics Northwest Biotherapeutics Celldex TVAX BioMed Agenus

  19. Market

  20. Future Growth MILESTONES/INFLECTION POINTS BEING MET 2012 2013 2014 2015 2016 $3.5MM Series A Launch EXIT WINDOW $10M Series B Build Company & Exit Transform Company & Exit $30M Series B If Needed

  21. Use of Funds • $500,000 to complete and expand Intellectual Property $250,000 to Complete IND Filing for Breast Cancer Vaccine $2.0 Million for Salaries, Hiring New Staff, Facilities, R&D on Novel Antigen Discovery (Est. 2 Yrs) $750,000 to Complete Phase 1b Breast Cancer Study $750,000 to Complete ICT Vaccine Phase 1b NSCLC Lung Cancer (37 Patients)

  22. Liquidity Event Conservative valuation of ICT at USD $17.5 Million • Strong Patent-Portfolio of Issued Patents • Phase 1b Trial that has commenced in NSCLC • IND Trial that is ready to be filed in Breast Cancer • Antigen Discovery Proprietary Technology (that has identified 20 New Cancer Immunotherapy Antigens to Date) • Contemporary Vaccine companies with single compound leads at Phase 2 with inferior DC technology and valuations in excess of $100MM • Positive Phase 1 Proof of Concept to increase valuation of Company and provide ROI- 1 year out • Post Phase 1 Strategy- Acquisition or Partnership or Public Offering

More Related